Lymphokine-Activated Killer Cells: Biology and Relevance to Disease

References

• Grimm E. A., Mazumber A., Zhang H. Z., et al. Lymphokine activated killer cell phenomenon. I. Lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–1841
   PubMed Web of Science ®Google Scholar
• Grimm E. A., Rosenberg S. A. The human lymphokine-activated killer cell phenomenon. Lymphokines, Vol 9, E. Pick. Academic Press, New York 1984; 279–311
   Google Scholar
• Rosenberg S. A., Lotze M. T. Cancer immunotherapy using interleukin-2 activated lymphocytes. Annual Review of Immunology, Vol 4, W. E. Paul, C. G. Fathman, H. Metzger, Palo Alto, CA 1986; 681–709, Annual Reviews
   Google Scholar
• Peace D. J., Kern D. E., Schultz K. R., et al. IL-4-induced lymphokine-activated killer cells: Lytic activity is mediated by phenolypically distinct natural killer-like and T cell-like large granular lymphocytes. J Immunol 1988; 140: 3679–3685
   PubMed Web of Science ®Google Scholar
• Mule J. J., Krosnick J. A., Rosenberg S. A. IL-4 regulation of murine lymphokine-activated killer activity in vitro: Effects on the IL-2-induced expansion, cytotoxicity and phenotype of LAK effectors. J Immunol 1989; 142: 726–733
   PubMed Web of Science ®Google Scholar
• Mule J. J., Smith K. A., Rosenberg S. A. Interleukin-4 (B cell stimulating factor-1) can mediate the induction of lymphokine activated killer cell activity directly against fresh tumor cells. J Exp Med 1987; 166: 792–804
   PubMed Web of Science ®Google Scholar
• Sone S., Utsugi T., Nii A., et al. Effects of human alveolar macrophages on the induction of lymphokine-activated killer cells. J Immunol 1987; 139: 29–34
   PubMed Web of Science ®Google Scholar
• Roth M. D., Golub S. H. Inhibition of lymphokine-activated killer cell function by human alveolar macrophages. Cancer Res 1989; 49: 4690–4695
   PubMed Web of Science ®Google Scholar
• Hiserodt J. C., Vujanovic N. L., Reynolds C. W., . Studies on lymphokine activated killer cells in the rat: Analysis of precursor and effector cell phenotype and relationship to natural killer cells. Cellular Immunotherapy of Cancer, R. L. Truitt, R. P. Gale, M. M. Bortin, et al. Alan R Liss, New York 1987; 137–146
   Google Scholar
• Vujanovic N. L., Herberman R. B., Hiserodt J. C. Lymphokine-activated killer cells in rats: Analysis of tissue and strain distribution, ontogeny and target specificity. Cancer Res 1988; 48: 878–883
   PubMed Web of Science ®Google Scholar
• Djeu J., Blanchard K. Lysis of human monocytes by lymphokine activated killer cells. Cell Immunol 1988; 111: 55–65
   PubMed Web of Science ®Google Scholar
• Strominger J. L. Developmental biology of T cell receptors. Science 1989; 244: 943–950
   PubMed Web of Science ®Google Scholar
• Borst J., VandeGriend R. J., Van Oostveen J. W., et al. A T cell re-pector gamma/CD3 complex found on cloned functional lymphocytes. Nature 1987; 325: 683–687
   PubMed Web of Science ®Google Scholar
• Matus L. A., Fry A. M., Cron R. Q., et al. Structure and specificity of a class II MHC alloreactive gamma/delta T cell receptor heterodimer. Science 1989; 245: 746–749
   PubMed Web of Science ®Google Scholar
• Spits H., Paliard X., DeVries J. E. Antigen-specific, but not natural killer activity of T cell receptor gamma/delta cytotoxic T lymphocyte clones involves secretion of BTL-esterase and influx of Ca++ ions. J Immunol 1989; 143: 1506–1510
   PubMed Web of Science ®Google Scholar
• Fitzgerald-Bocarsky P., Herberman R. B., Hiserodt J. C., . A definition of natural killer cells. Natural Killer Cells and Host Defense, E. W. Ades, C. Lopez, et al. Karger, New York 1989; 13
   Google Scholar
• Reynolds C. W., Bonyhardi M., Herberman R. B., et al. Lack of gene rearrangement and mRNA expression of the beta chain of the T cell receptor in spontaneous rat large granular lymphocyte leukemia lines. J Exp Med 1985; 161: 1249–1254
   PubMed Web of Science ®Google Scholar
• Lanier L. L., Cwirla S., Federspiel N., et al. Human natural killer cells isolated from peripheral blood do not rearrange T cell antigen receptor beta cain genes. J Exp Med 1986; 163: 209–218
   PubMed Web of Science ®Google Scholar
• Biron C. A., Vanden Elson P., Tutt M., et al. Murine natural killer cells stimulated in vivo do not express T cell receptor alpha, beta, gamma, T3 delta or T3 epsilon genes. J Immunol 1987; 139: 1704–1709
   PubMed Web of Science ®Google Scholar
• Tutt M., Kujiel W. A., Hackett J., et al. Murine natural killer cells do not express functional transcripts of the alpha, beta or gamma chain genes of the T cell receptor. J Immunol 1986; 137: 2998–3004
   PubMed Web of Science ®Google Scholar
• Ritz J., Campen J., Schmidt R. E., et al. Analysis of T cell receptor gene rearrangements and expression in human natural killer cell clones. Science 1985; 228: 1540–1541
   PubMed Web of Science ®Google Scholar
• Karre K., Ljunggren H., Prontek G., et al. Selective rejection of H-2 deficient lymphoma varients suggests an alternative immune defense strategy. Nature 1986; 319: 679–681
   Google Scholar
• Gorelik E., Gunji Y., Herberman R. B. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity. J Immunol 1988; 140: 2096–2102
   PubMed Web of Science ®Google Scholar
• Henkart P. Mechanism of lymphocyte mediated cytotoxicity. Annual Review of Immunology, Vol 3, W. E. Paul, C. G. Fathman, H. Metzger, Palo Alto, CA 1985; 31–58, Annual Reviews
   Google Scholar
• Ortaldo J. R., Hiserodt J. C. Mechanism of cytotoxicity by natural killer cells. Current Opinion in Immunology, H. J. Muller. Eberhard, London, 2: 39
   Google Scholar
• Perussia B., Trinchieri G. Antibody 3G8, specific for human neu-trophil Fc receptor, reacts with natural killer cells. J Immunol 1984; 132: 1410–1415
   PubMed Web of Science ®Google Scholar
• Phillips J. H., Babcock G. F. NKP-15: A monoclonal antibody against purified human natural killer cells and granulocytes. Immunol Lett 1983; 6: 143–147
   PubMed Web of Science ®Google Scholar
• Hercend T., Griffen J. D., Bensussan, et al. Generation of monoclonal antibodies to human NK clones: Characterization of two NK associated antigens NKH1 and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest 1985; 75: 932–938
   PubMed Web of Science ®Google Scholar
• Koo G. C., Peppard J. R., Hatzfield A. Ontogeny of NK-1+ natural killer cells I. Proportion of NK-1 cells in fetal, baby and mice. J Immunol 1981; 10: 175–179
   Google Scholar
• Kasai M., Iwamori M., Nasai Y., et al. A glycolipid on the surface of mouse natural killer cells. Eur J Immunol 1981; 10: 175–179
   Web of Science ®Google Scholar
• Chambers W. H., Vujanovic N. L., DeLeo A. B., et al. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med 1989; 169: 1373–1379
   PubMed Web of Science ®Google Scholar
• Reynolds C. W., Sharrow S. O., Ortaldo J. R., et al. Natural killer activity on the rat. II. Analysis of surface antigens on LGL by flow cytometry. J Immunol 1981; 127: 2204–2210
   PubMed Web of Science ®Google Scholar
• Woda B. A., McFadden M. L., Walsh R. M., et al. Separation and isolation of rat natural killer cells from T cells with monoclonal antibodies. J Immunol 1984; 132: 2132–2186
   Google Scholar
• Herberman R. B., Ortaldo J. R. Natural killer cells: Their roles in defense against disease. Science 1981; 214: 24–30
   PubMed Web of Science ®Google Scholar
• Hiserodt J. C., Herberman R. B. Natural killer cells and tumor immunity, 1989. The Year in Immunology, J. Cruse. Karger, New York 1989; 201–207
   Google Scholar
• Grimm E. A., Ramsey K. M., Mazumder A., et al. Lymphokine activated killer cell phenomenon. II. The precursor cells are serologically distinct from peripheral T lymphocytes, memory CTL and NK cells. J Exp Med 1983; 157: 884–897
   PubMed Web of Science ®Google Scholar
• Ballas Z. K. Lymphokine activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide. J Immunol 1986; 137: 2380–2389
   PubMed Web of Science ®Google Scholar
• Andriole G. L., Mul J. J., Hansen C. T., et al. Evidence that lymphokine activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice. J Immunol 1985; 135: 2911–2913
   PubMed Web of Science ®Google Scholar
• Merluzzi V. J., Smith D. M., Last-Barney K. Similarities and distinctions between murine natural killer cells and lymphokine activated killer cells. Cell Immunol 1986; 100: 563–572
   PubMed Web of Science ®Google Scholar
• Ballas Z. K., Rasmussen W., VanOteghan J. K. Lymphokine activated killer cells. II. Delineation of distinct murine LAK precursor subpopulations. J Immunol 1986; 138: 1647–1652
   Web of Science ®Google Scholar
• Herberman R. B., Hiserodt J. C., Vujanovic N. K., et al. Lymphokine activated killer cell activity: Characteristics of effector cells and progenitor cells in blood and spleen. Immunol Today 1987; 8: 178–181
   PubMedGoogle Scholar
• Ortaldo J. R., Mason A., Overton R. Lymphokine activated killer cells. Analysis of progenitors and effectors. J Exp Med 1986; 165: 1193–1205
   Google Scholar
• Phillips J. H., Lanier L. L. Dissection of the lymphokine activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814–825
   PubMed Web of Science ®Google Scholar
• Itoh K., Tilten B., Kumagai K., et al. Leu 11+ lymphocytes with natural killer activity are precursors of recombinant interleukin-2 (rIL-2) induced activated killer cells. J Immunol 1985; 134: 802–807
   PubMed Web of Science ®Google Scholar
• Lanier L. L., Benika J., Phillips J. H., et al. Recombinant interleukin-2 enhanced natural killer cell mediated cytotoxicity in human lymphocyte subpopulations expressing Leu7 and Leul 1 antigens. J Immunol 1985; 134: 794–801
   PubMed Web of Science ®Google Scholar
• Schmidt R. E., Murray C., Daley J. F., et al. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 1986; 164: 351–357
   PubMed Web of Science ®Google Scholar
• Lanier L. L., Kipps T. J., Phillips J. H. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leull antigen). J Exp Med 1985; 163: 2089–2016
   Google Scholar
• Anderson P. M., Blazar B., Bach F. H., et al. Anti-CD3 plus IL-2 stimulated murine killer cells. In vitro generation and in vivo anti-tumor activity. J Immunol 1989; 142: 1383–1394
   PubMed Web of Science ®Google Scholar
• Morris D. G., Pross H. F. Studies on lymphokine activated killer cells. Evidence using novel monoclonal antibodies that most human LAK precursor cells share in common surface marker. J Exp Med 1989; 169: 717–736
   PubMed Web of Science ®Google Scholar
• Shau H., Golub S. H. Depletion of NK cells with the lysosomotrophic agent L-leucine methyl ester and the in vitro generation NK activity from NK precursor cells. J Immunol 1985; 143: 1136–1141
   Google Scholar
• Yang J. C., Mule J. J., Rosenberg S. A. Murine lymphokine activated killer (LAK) cells: Phenotypic characterization of the precursor and effector cells. J Immunol 1986; 137: 715–722
   PubMed Web of Science ®Google Scholar
• Salup R. R., Matheson B. J., Wiltrout R. H. Precursor phenotype of lymphokine activated killer (LAK) cells in the mouse. J Immunol 1987; 138: 3635–3639
   PubMed Web of Science ®Google Scholar
• Vujanovic N. K., Herberman R. B., Olszowy M. W., et al. Lymphokine activated killer cells in rats: Analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Cancer Res 1988; 48: 884–890
   PubMed Web of Science ®Google Scholar
• Vujanovic N. K., Herberman R. B., Hiserodt J. C. Lymphokine activated killer cells in rats. II. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine activated killer cells. J Exp Med 1988; 167: 15–29
   PubMed Web of Science ®Google Scholar
• Muul L. M., Director E. P., Hyatt C. L., et al. Large scale production of human lymphokine activated killer cells for use in adoptive immunotnerapy. J Immunol Methods 1986; 88: 625–634
   Google Scholar
• Gunji Y., Vujanovic N. L., Hiserodt J. C., et al. Generation and characterization of purified adherent lymphokine activated killer cells in mice. J Immunol 1989; 142: 1748–1754
   PubMed Web of Science ®Google Scholar
• Chang H. L., Zaroukian M. H., Morrison M. H., et al. Adherent lymphokine activated natural killer cells in normal and SCID mice: Large granular lymphocytes with natural killer phenotype and high cytolytic activity. Nat Immun Cell Growth Regul 1989; 8: 89–99
   PubMedGoogle Scholar
• Melder R. J., Whiteside T. L., Vujanovic N. L., et al. A new approach to generating anti-tumor effectors for adoptive immunotherapy using human adherent lymphokine activated killer cells. Cancer Res 1988; 48: 1461–1469
   Google Scholar
• Schwarz R. E., Hiserodt J. C. The importance of splenectomy for the adoptive immunotherapy of cancer. Med Hypotheses 1989; 28: 165–168
   PubMed Web of Science ®Google Scholar
• Whiteside T. L., Wang Y. L., Selker R. S., et al. In vitro generation and anti-tumor activity of adherent lymphokine activated killer cells from the blood of patients with brain tumors. Cancer Res 1988; 48: 6069–6075
   PubMed Web of Science ®Google Scholar
• Timonen T., Ortaldo J. R., Herberman R. B. Characteristics of human large granular lymphocytes and relationship to natural killer cells and K cells. J Exp Med 1981; 153: 569–582
   PubMed Web of Science ®Google Scholar
• Itoh K., Suzaki R., Umeyu Y., et al. Studies on murine large granular lymphocytes. II. Tissue, strain, age and distributions of LGL and LAL. J Immunol 1982; 129: 395–399
   PubMed Web of Science ®Google Scholar
• Hackett J. M., Bennett M., Kumar V. Origin and differentiation of natural killer cells. I. Characteristics of a transplantable NK cells precursor. J Immunol 1985; 134: 3731–3735
   PubMed Web of Science ®Google Scholar
• Hackett J. M., Tutt M., Lipscomb M., et al. Origin and differentiation of natural killer cells. II. Functional and morphologic studies of purified NK1.1+ cells. J Immunol 1986; 136: 124–128
   Google Scholar
• Shau H., Golub S. H. Depletion of NK cells with the iysoso-motrophic agent L-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells. J Immunol 1985; 134: 1136–1140
   PubMed Web of Science ®Google Scholar
• Maghazachi A. A., Vujanovic N. K., Herberman R. B., et al. Lymphokine activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes and lymphokine activated killer cells. J Immunol 1988; 140: 2846–2852
   PubMed Web of Science ®Google Scholar
• Koo G. C., Peppard J. R., Lattine E. C. Characterization of cytotoxic cells generated for bone marrow culture. Cell Immunol 1986; 98: 172–181
   PubMed Web of Science ®Google Scholar
• Migliorati G., Cannarile L., Herberman R. B., et al. Role of IL-2 and hemopoietin-1 in the generation of mouse natural killer cells from primitive bone marrow precursors. J Immunol 1987; 138: 2618–2624
   Google Scholar
• Kaltand T. Generation of natural killer cells from bone marrow precursors in vitro. Immunology 1986; 57: 493–504
   PubMed Web of Science ®Google Scholar
• Sarneva M., Vujanovic N. L., Van Den Brink M. RM, et al. Lymphokine activated killer cells in rats: Generation of natural killer cells and lymphokine activated killer cells from bone marrow progenitor cells. Cell Immunol 1989; 118: 448–457
   PubMed Web of Science ®Google Scholar
• Van Den Brink M. RM, Boggs S. S., Hiserodt J. C. Characterization of NK/LAK progenitor cells in long term rat bone marrow cultures. Nat Immun Cell Growth Regul 1989; 8: 124–126
   Google Scholar
• Van Den Brink M. RM, Boggs S. S., Hiserodt J. C. The generation of natural killer cells from enriched progenitor cells in rat long term bone marrow cultures. J Exp Med 1990; 172: 303–313
   PubMed Web of Science ®Google Scholar
• Shau H., Shen D., Golub S. H. The role of transferrin receptors in natural killer cell and IL-2 induced cytotoxic cell function. Cell Immunol 1985; 112: 121–130
   Google Scholar
• Shau H., Golub S. H. Inhibition of lymphokine activated killer and natural killer cytotoxicity by neutrophils. J Immunol 1989; 143: 1066–1072
   PubMed Web of Science ®Google Scholar
• Shau H., Golub S. H. Modulation of natural killer mediated lysis by red blood cells. Cell Immunol 1988; 116: 60–72
   PubMed Web of Science ®Google Scholar
• Owen-Schaub L. B., Gutterman J. U., Grimm E. A. Effect of tumor necrosis factor alpha and IL-2 in the generation of human lymphokine activated killer cell cytotoxicity. Cancer Res 1988; 48: 788–792
   PubMed Web of Science ®Google Scholar
• Ochoa A. C., Giomo G., Alter R. J., et al. Long term growth of LAK cells: Role anti-CD3, IL-1, interferon-gamma and beta. J Immunol 1987; 138: 2728–2732
   PubMed Web of Science ®Google Scholar
• Mule J. J., Schwarz S. L., Robert J., et al. Transforming growth factor beta inhibits the generation of lymphokine activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 1988; 26: 95–103
   PubMed Web of Science ®Google Scholar
• Grimm E. A., Cruppin W. L., Durett A., et al. TGF-beta inhibits the induction of lymphokine activated killer activity. Cancer Immunol Immunother 1988; 27: 53–62
   PubMed Web of Science ®Google Scholar
• Greene W. C., Bohnlein E., Ballard D. W. HIV-1, HTLV-1 and normal T cell growth: Transcriptional strategies and surprises. Immunol Today 1989; 10: 272–278
   PubMedGoogle Scholar
• Robb R. T., Rusk C. M., Yodi J., et al. Interleukin-2 binding molecules distinct from the Tac protein: Analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci USA 1987; 94: 2002–2006
   Google Scholar
• Bich-Thuy L. T., Dakovich M., Peffer N. J., et al. Direct activation of human resting T cells by IL-2: The role of an IL-2 receptor distinct from the TAC protein. J Immunol 1987; 139: 1550–1556
   PubMed Web of Science ®Google Scholar
• Phillip J. H., Takeshita T., Sugamora K., et al. Activation of natural killer cells via the p75 interleukin-2 receptor. J Exp Med 1989; 170: 291–296
   PubMed Web of Science ®Google Scholar
• Hiserodt J. C., Chambers W. H. Role of soluble cytotoxic factors in lymphokine activated killer cell mediated cytotoxicity. Ann NY Acad Sci 1988; 532: 395–404
   PubMedGoogle Scholar
• Hiserodt J. C. Some thoughts on the cytolytic activity of natural killer lymphocytes. Cancer Cells 1991; 3(12)530
   PubMed Web of Science ®Google Scholar
• Timonen T., Patrarroyo M., Gahmberg C. G. CDlla-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J Immunol 1988; 141: 1041–1046
   PubMed Web of Science ®Google Scholar
• Girodo R., Rudert W. A., Vavassori C., et al. NKR-P1, a novel signal transduction molecule on NK cells. Science 1990; 249: 1298–1301
   PubMed Web of Science ®Google Scholar
• Ryan J. C., Niemi E. C., Hiserodt J. C. NKR-PI, an activating molecule on rat NK cells, simulates phosphoinositide turnover and a rise in intracellular calcium. J Immunol 1991; 147: 3244–3250
   PubMed Web of Science ®Google Scholar
• Felgar R. E., Hiserodt J. C. Identification and partial characterization of a novel plasma membrane-associated lytic factor isolated from highly purified adherent lymphokine-activated killer cells. Cell Immunol 1992; 141: 32–46
   PubMed Web of Science ®Google Scholar
• DeFries R. U., Golub S. H. Interferon-gamma reduces the sensitivity of cultured and fresh human tumor cells to lysis by lymphokine activated killer cells. Nat Immun Cell Growth Regul 1988; 7: 65–76
   PubMedGoogle Scholar
• Adler A., Chervenick P. A., Whiteside T. L., et al. IL-2 induction of LAK activity in acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 1988; 71: 709–716
   PubMed Web of Science ®Google Scholar
• Hiserodt J. C., Van Den Brink M. RM, Schwarz R. E. Surface structures involved in target recognition by lymphokine activated killer cells. Interleukin-2 Activated Killer Cells, E. Lotzova, R. B. Herberman. CRC Press, Boca Raton, FL 1990; 351–361
   Google Scholar
• Bukowski J. F., Biron C. A., Welsh R. M. Elevated natural killer cell mediated cytotoxicity, plasma interferon, and tumor cell rejection in mice persistently infected with lymphocytic choriomeningitis virus. Immunology 1983; 131: 991–997
   Web of Science ®Google Scholar
• Minato N., Bloom B. R., Jones C., et al. Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice. J Exp Med 1979; 194: 1117–1128
   Google Scholar
• Ojo E. Positive correlation between the levels of natural killer cells and the in vivo resistance to syngeneic tumor transplant as influenced by various routes of administration of Corynebacterium parvum bacteria. Cell Immunol 1979; 45: 182–190
   PubMed Web of Science ®Google Scholar
• Habu S., Fukui H., Shimamura K., et al. In vivo effects of antiasialo GMI I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 1981; 127: 34–38
   PubMed Web of Science ®Google Scholar
• Pollack S. B., Hallenbeck L. A. In vivo reduction of NK activity with anti-NKl serum: Direct evaluation of NK cells in tumor clearance. Int J Cancer 1982; 29: 203–207
   PubMed Web of Science ®Google Scholar
• Pollack S. B. Direct evidence of anti-tumor activity by NK cells in vivo: Growth of B16 melanoma in anti-NK 1.1 treated mice. NK Cells and Other Natural Effector Cells, R. B. Herberman. Academic Press, New York 1982; 1347–1352
   Google Scholar
• Seaman W. E., Sleisenger M., Koo G. C. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1 Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 1987; 138: 4359–4546
   Google Scholar
• Van Den Brink M. RM, Hunt L. E., Hiserodt J. C. In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats. J Exp Med 1990; 171: 197–209
   PubMed Web of Science ®Google Scholar
• Talmadge J. E., Meyers K. M., Prieur D. J. Role of NK cells in tumor growth metastasis in beige mice. Nature 1980; 284: 622–624
   PubMed Web of Science ®Google Scholar
• Gorelik I., Fogel M., Feldman D., et al. Differences in resistance of metastatic tumor cells and cells from local tumor growth to cytotoxicity of natural killer cells. JNCI 1979; 63: 1397–1402
   PubMed Web of Science ®Google Scholar
• Hanna N., Burton R. D. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastatic in vivo. J Immunol 1981; 127: 1754–1759
   PubMed Web of Science ®Google Scholar
• Barlozzarri T., Leonhardt J., Wiltrout R. H. Direct evidence for the role of LGL in the inhibition of experimental tumor me-tastases. J Immunol 1985; 134: 2783–2787
   PubMed Web of Science ®Google Scholar
• Mazumder A., Rosenberg S. A. Successful immunotherapy of NK-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 1984; 159: 495–507
   PubMed Web of Science ®Google Scholar
• La Freneire R., Rosenberg S. A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine activated killer cells and recombinant interleukin-2. Cancer Res 1985; 45: 3735–3741
   PubMed Web of Science ®Google Scholar
• Mule J. J., Shu S., Schwarz S. L., et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant inierleukin-2. Science 1984; 225: 1487–1489
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Important Advances in Oncology, V. T. DeVita, S. Hell-Man, S. A. Rosenberg. Lippincott, Philadelphia 1986; 55–91
   Google Scholar
• Salup R. R., Wiltrout R. H. Adjuvant immunotherapy of established murine renal cancer by interleukin-2 stimulated cytotoxic lymphocytes. Cancer Res 1986; 46: 3358–3363
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987; 316: 88–8987
   Google Scholar
• Lotze Mt, Chang A. E., Seipp C. A., et al. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related morbidity and histologic findings. JAMA 1986; 256: 3117–3124
   PubMed Web of Science ®Google Scholar
• Gemlo B. T., Palladino M. A., Jaffe H. S., et al. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine activated killer cells. Cancer Res 1988; 48: 5864–5867
   PubMed Web of Science ®Google Scholar
• Kotasek D., Vercallotti G. M., Ochoa A. C., et al. Mechanisms of cultured endothelial injury by lymphokine activated killer cells. Cancer Res 1988; 48: 5528–5532
   PubMed Web of Science ®Google Scholar
• West W. H., et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905
   PubMed Web of Science ®Google Scholar
• Nishimura T., Togashi Goto M., et al. Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin-2. Cancer Immunol Immunother 1986; 21: 12–18
   PubMed Web of Science ®Google Scholar
• Schoof D. D., Gramolini B. A., Davidson D. L., et al. Adoptive immunotherapy of human cancer using low dose recombinant interleukin-2 and lymphokine activated killer cells. Cancer Res 1988; 48: 5007–5010
   PubMed Web of Science ®Google Scholar
• Schwarz R. E., Hiserodt J. C. The importance of splenectomy for adoptive immunotherapy of cancer. Med Hypothesis 1989; 28: 165–168
   PubMed Web of Science ®Google Scholar
• Schwarz R. E., Vujanovic N. L., Hiserodt J. C. Enhanced antimeta-static activity of lymphokine activated killer cells purified and expanded by their adherence to plastic. Cancer Res 1989; 49: 1141–1446
   Google Scholar
• Maghazachi A. A., Vujanovic N. L., Herberman R. B., et al. In vivo distribution and tissue localization of high purified rat lymphokine activated killer cells. Cell Immunol 1988; 115: 179–193
   PubMed Web of Science ®Google Scholar
• Rolstad B., Herberman R. B., Reynolds C. W. Circulation patterns and tissue localization of peripheral blood large granular lymphocyte (LGL). J Immunol 1986; 136: 2800–2808
   PubMed Web of Science ®Google Scholar
• Felgar R. E., Hiserodt J. C. In vivo migration patterns of highly purified adherent lymphokine activated killer cells in tumor bearing rats. Cell Immunol 1992; 141: 32
   PubMed Web of Science ®Google Scholar
• Hornung R. L., Salup R. R., Wiltrout R. H. Tissue distribution and localization of IL-2 activated killer cells after adoptive transfer in vivo. Interleukin-2 and Killer Cells in Cancer, E. Lotzova, R. B. Herberman. CRC Press, Boca Raton, FL 1990; 245–258
   Google Scholar
• Basse P., Herberman R. B., Nannmark U. Accumulation of adoptively transferred adherent lymphokine-activated killer cells in murine metastases. J Exp Med 1991; 174: 479–488
   PubMed Web of Science ®Google Scholar
• Long G. S., Harnaha J., Hiserodt J. C., et al. Lymphokine activated killer cell purging of leukemic bone marrow prior to autologous bone marrow transplantation. Transplantation 1988; 46: 433–438
   PubMed Web of Science ®Google Scholar
• Van Den Brink M. RM, Voogt P. J., Marift W. AF, et al. Lymphokine activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell functions in vitro. Blood 1989; 74: 354–360
   PubMed Web of Science ®Google Scholar
• Van Den Brink M. RM, Voogt P. J., Long G. S., . LAK cells and autologous bone marrow transplantation: Towards a cure for leukemia. Interleukin-2 Activated Cells, E. Lotzova, R. B. Herberman, et al. CRC Press, Boca Raton, FL 1990; 219–233
   Google Scholar
• Voogt P. J., Falkenberg J. H., Fibbe W. E., et al. Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell melted MHC nonre-stricted lysis by TcR-/CD3-, TcR gamma/delta+/CD3 + and TcR alpha/beta+/CD3+ lymphocytes. J Immunol 1989; 142: 1779–1780
   Google Scholar
• Long G. S., Cramer D. V., Hiserodt J. C. Lymphokine-activated killer cell purging of leukemic bone marrow: Range of activity against different hematopoietic neoplasms. Bone Marrow Transplant 1990; 8: 294–304
   Google Scholar
• Bukowski J. F., Warner J., Dennert G., et al. Adoptive transfer studies demonstrating the antiviral effect of NK cells in vivo. J Exp Med 1985; 161: 40–52
   PubMed Web of Science ®Google Scholar
• Bukowski J. F. Antiviral effects of lymphokine activated killer cells. Natural Killer Cells and Host Defense, E. W. Ades, C. Lopex. Karger, Basel 1989; 131–135
   Google Scholar